Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes

Oncology Letters

Volumn 12, Issue 1, 2016, Pages 375-378

  Xie, Yingqiu ^a   Naizabekov, Sanzhar ^a   Chen, Zhanlin ^b   Tokay, Tursonjan ^a  

^a NAZARBAYEV UNIVERSITY   (Kazakhstan)

^b LIPSCOMB UNIVERSITY   (United States)

Author keywords

Molecular switch; Oncogene; PTEN; Tumor suppressor

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SLUG;

BREAST CANCER; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVATION; GENE DELETION; HUMAN; ONCOGENE; OPEN READING FRAME; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 84973443327     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4636     Document Type: Review

References (40)

1. Gustafson S, Zbuk KM, Scacheri C and Eng C: Cowden syndrome: Semin Oncol 34: 428-434, 2007.
2. Blumenthal GM and Dennis PA: PTEN hamartoma tumor syndromes. Eur J Hum Genet 16: 1289-1300, 2008.
3. Feilotter HE, Nagai MA, Boag AH, Eng C and Mulligan LM: Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16: 1743-1748, 1998.
4. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS and Sidransky D: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997-5000, 1997.
5. Song MS, Salmena L and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13: 283-296, 2012.
6. Ackler S, Ahmad S, Tobias C, Johnson MD and Glazer RI: Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 21: 198-206, 2002.
7. Bargonetti J and Manfredi JJ: Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14: 86-91, 2002.
8. Di Cristofano A and Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 100: 387-390, 2000.
9. Di Cristofano A, Pesce B, Cordon-Cardo C and Pandolfi PP: Pten is essential for embryonic development and tumor suppression. Nat Genet 19: 348-355, 1998.
10. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3: 973-982, 2001.
11. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262-267, 1998.
12. Mayo LD, Dixon JE, Durden DL, Tonks NK and Donner DB: PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277: 5484-5489, 2002.
13. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730, 2005.
14. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, et al: PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell 3: 117-130, 2003.
15. Lowe SW, Cepero E and Evan G: Intrinsic tumor suppression. Nature 432: 307-315, 2004.
16. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y: Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039-43, 2002.
17. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, et al: EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 338: 1465-1469, 2012.
18. Liu DC and Yang ZL: Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 207: 472-478, 2011.
19. Zeng N, Yang KT, Bayan JA, He L, Aggarwal R, Stiles JW, Hou X, Medina V, Abad D, Palian BM, et al: PTEN controls β-cell regeneration in aged mice by regulating cell cycle inhibitor p16ink4a. Aging Cell 12: 1000-1011, 2013.
20. Vredeveld LC, Rowland BD, Douma S, Bernards R and Peeper DS: Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis 31: 201-207, 2010.
21. Qu H, Qu D, Chen F, Zhang Z, Liu B and Liu H: ZBTB7 overexpression contributes to malignancy in breast cancer. Cancer Invest 28: 672-678, 2010.
22. Zhao ZH, Wang SF, Yu L, Wang J, Chang H, Yan WL, Zhang J and Fu K: Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results. Lung Cancer 62: 113-119, 2008.
23. Aggarwal A, Hunter WJ III, Aggarwal H, Silva ED, Davey MS, Murphy RF and Agrawal DK: Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers. Exp Mol Pathol 89: 140-148, 2010.
24. Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, et al: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet 45: 739-746, 2013.
25. den Besten W, Kuo ML, Tago K, Williams RT and Sherr CJ: Ubiquitination of and sumoylation by, the Arf tumor suppressor. Isr Med Assoc J 8: 249-251, 2006.
26. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, et al: Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103: 5947-5952, 2006.
27. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE, Krimpenfort P, Depinho RA, Bennett DC, Sviderskaya EV and Merlino G: ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA 104: 10968-10973, 2007.
28. Chen Z, Carracedo A, Lin HK, Koutcher JA, Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W, Teruya-Feldstein J, et al: Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal 2: ra44, 2009.
29. Humbey O, Pimkina J, Zilfou JT, Jarnik M, Dominguez-Brauer C, Burgess DJ, Eischen CM, Murphy ME: The ARF tumor suppressor can promote the progression of some tumors. Cancer Res 68: 9608-9613, 2008.
30. Khoo CM, Carrasco DR, Bosenberg MW, Paik JH and Depinho RA: Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc Natl Acad Sci USA 104: 3931-3936, 2007.
31. Hajra KM, Chen DY and Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 62: 1613-1618, 2002.
32. Xie Y, Liu S, Lu W, Yang Q, Williams KD, Binhazim AA, Carver BS, Matusik RJ and Chen Z: Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Mol Oncol 8: 1355-3564, 2014.
33. Halvorsen OJ, Haukaas SA and Akslen LA: Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 9: 1474-1479, 2003.
34. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, et al: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153-1160, 2002.
35. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J and Arteaga CL: PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8: 1145-1152, 2002.
36. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, et al: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8: 1136-1144, 2002.
37. Mullan PB, Quinn JE and Harkin DP: The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25: 5854-5863, 2006.
38. Wang H, Yang ES, Jiang J, Nowsheen S and Xia F: DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Cancer Res 70: 6258-6267, 2010.
39. Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, Wang Y, Billheimer D, Chakravarthy AB, Brown M, et al: p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res 71: 5546-5557, 2011.
40. Nelson AC, Lyons TR, Young CD, Hansen KC, Anderson SM and Holt JT: AKT regulates BRCA1 stability in response to hormone signaling. Mol Cell Endocrinol 319: 129-142, 2010.